Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients
- PMID: 16686650
- DOI: 10.1111/j.1528-1167.2006.00553.x
Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients
Abstract
Purpose: To assess the long-term evolution of Unverricht-Lundborg disease (ULD), especially concerning myoclonus, seizures, and EEG characteristics.
Methods: We retrospectively evaluated 20 patients (six women, 14 men; mean age, 37.9 years; range, 26-53 years) with ULD who had been closely followed up since the onset of the disease (mean age, 12.3 years; range, 6-17 years) for an average of 25.6 years (range, 13-41 years). ULD was confirmed by genetic tests in all. We used simplified myoclonus and seizure rating scales.
Results: The geographic origin of the patients was Northern Africa in nine, France in two, Italy in six, and mixed European in three. Three patients were severely handicapped, six led fully autonomous lives, and 11 required various degrees of social support. Myoclonus progressed only during the first 5 years of disease. Major seizures occurred in 19. Three patients had a single seizure, and eight became seizure free, whereas six had rare seizures, and two had frequent attacks. Overall, seizures became much less frequent after 10 years of evolution. EEG changes abated during follow-up: background activity remained stable or improved, spontaneous discharges disappeared, and photoparoxysmal responses were abolished in all patients but two.
Conclusions: This study shows that ULD progresses only over a limited period and stabilizes thereafter. This self-limited progression may be the consequence of age-related apoptosis of selected neuronal populations.
Similar articles
-
Long-term evolution of EEG in Unverricht-Lundborg disease.Epilepsy Res. 2007 Mar;73(3):219-27. doi: 10.1016/j.eplepsyres.2006.10.006. Epub 2006 Dec 8. Epilepsy Res. 2007. PMID: 17158032
-
Unverricht-Lundborg progressive myoclonus epilepsy in Oman.Pediatr Neurol. 2008 Apr;38(4):252-5. doi: 10.1016/j.pediatrneurol.2007.11.006. Pediatr Neurol. 2008. PMID: 18358403
-
Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations.Epilepsia. 2004 Jun;45(6):678-81. doi: 10.1111/j.0013-9580.2004.56902.x. Epilepsia. 2004. PMID: 15144434 Clinical Trial.
-
Clinical picture of EPM1-Unverricht-Lundborg disease.Epilepsia. 2008 Apr;49(4):549-56. doi: 10.1111/j.1528-1167.2008.01546.x. Epub 2008 Mar 5. Epilepsia. 2008. PMID: 18325013 Review.
-
[Unverricht-Lundborg disease (PME1)].Rev Neurol (Paris). 2006 Sep;162(8-9):819-26. doi: 10.1016/s0035-3787(06)75084-6. Rev Neurol (Paris). 2006. PMID: 17028542 Review. French.
Cited by
-
Update on Pharmacological Treatment of Progressive Myoclonus Epilepsies.Curr Pharm Des. 2017;23(37):5662-5666. doi: 10.2174/1381612823666170809114654. Curr Pharm Des. 2017. PMID: 28799509 Free PMC article. Review.
-
Genetics of epilepsy and relevance to current practice.Curr Neurol Neurosci Rep. 2012 Aug;12(4):445-55. doi: 10.1007/s11910-012-0281-8. Curr Neurol Neurosci Rep. 2012. PMID: 22618127 Review.
-
Progressive myoclonic epilepsies: definitive and still undetermined causes.Neurology. 2014 Feb 4;82(5):405-11. doi: 10.1212/WNL.0000000000000077. Epub 2014 Jan 2. Neurology. 2014. PMID: 24384641 Free PMC article.
-
Myoclonus-Ataxia Syndromes: A Diagnostic Approach.Mov Disord Clin Pract. 2020 Nov 3;8(1):9-24. doi: 10.1002/mdc3.13106. eCollection 2021 Jan. Mov Disord Clin Pract. 2020. PMID: 33426154 Free PMC article. Review.
-
ILAE Genetics Literacy series: Progressive myoclonus epilepsies.Epileptic Disord. 2023 Oct;25(5):670-680. doi: 10.1002/epd2.20152. Epub 2023 Sep 6. Epileptic Disord. 2023. PMID: 37616028 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical